Cerebrolysin is a neurotrophic drug, typically a peptide mixture derived from porcine brain proteins, utilized clinically for its neuroprotective and neurorestorative properties. It contains low-molecular-weight biologically active peptides that mimic the action of endogenous neurotrophic factors, supporting neuronal survival, differentiation, and synaptic plasticity. While not a classic hormone, its impact on central nervous system function is relevant to the neuro-endocrine axis and cognitive health.
Origin
This pharmaceutical agent originated in Austria and has been in clinical use for decades, primarily in Eastern Europe and parts of Asia, for the treatment of various neurological disorders, including stroke and dementia. Its development was based on the premise that a mixture of naturally occurring brain peptides could support damaged neural tissue.
Mechanism
The mechanism of action is pleiotropic, involving the modulation of neurotrophic factor signaling pathways, such as those related to nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Cerebrolysin is believed to penetrate the blood-brain barrier to reduce excitotoxicity, suppress free radical formation, and promote protein synthesis in neurons. By supporting neuronal metabolism and preventing apoptosis, it aids in the functional recovery of the central nervous system, indirectly influencing the regulatory centers of the endocrine system.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.